The European Commission (EC) has already approved Valneva’s chikungunya vaccine Ixchiq for use in individuals aged 18 years ...

The company’s rabies candidate, RBI-4000, was able to elicit an immune response comparable to Bavarian Nordic’s RavAvert.

First chikungunya vaccine recommended by the CHMP for persons as young as 12 years old.The virus-like particle (VLP) single-dose chikungunya ...

The details for each transaction made under the share repurchase program are published on bavarian-nordic.com. Following these transactions, Bavarian Nordic holds a total of 1,044,510 treasury ...

The consolidated, audited financial results for 2024 will become available on March 5, 2025, in connection with the publication of the Company's Annual Report for 2024. 2025 financial guidance For ...

Valneva's Ixchiq vaccine – which was cleared in the EU, the US, and Canada last year – is currently indicated for preventing ...

About Bavarian NordicBavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox ...

COPENHAGEN, Denmark, January 31, 2025 – Bavarian Nordic A/S (OMX: BAVA) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA ...

Bavarian Nordic A/S (OMX: BAVA) announces that the share buy-back program, which was announced and initiated on January 9, ...

Financial guidance for 2025 in line with the Company’s 2024-2027 ambitions. COPENHAGEN, Denmark, February 3, 2025 – Bavarian Nordic A/S (OMX: BAVA) today announced preliminary, unaudited financial ...